Loading company
Outset Medical, Inc.
OM · Nasdaq · ·
Next earnings: November 9, 2026
$3.01+1.5%Sep 29 close
- 1M
- -23.6%
- 6M
- -16.6%
- 1Y
- -78.7%
- 5Y
- -99.6%
OM · Nasdaq · ·
Next earnings: November 9, 2026
$3.01+1.5%Sep 29 close
Outset Medical, Inc. is scheduled to report next on November 9, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $31.6M | $31.4M | +0.69% |
| Profit | -$18M | -$18.5M | +3.00% |
| Profit per share | -$0.97 | -$1.04 | +6.73% |
| Free Cash Flow | -$9.7M | -$5.1M | -90.54% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“Second quarter results reflect continued progress in strengthening the foundation of our business while positioning Outset for the next phase of growth,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Outset is a medical technology company transforming the dialysis experience across the continuum of care with a first-of-its-kind technology. The Tablo® Hemodialysis System, FDA-cleared for use from hospital to home, is trusted by more than 1,000 U.S. healthcare facilities and has enabled millions of treatments delivered by thousands of nurses. Designed to reduce the cost and complexity of dialysis, Tablo combines water purification and on-demand dialysate production into a single, integrated system that connects seamlessly with Electronic Medical Record systems and a proprietary data analytics platform. This enterprise solution empowers providers to develop an in-house dialysis program where they are in control – enabling better operational, clinical, and financial outcomes. Outset is redefining what’s possible in kidney care through innovation, scale, and a relentless commitment to improving the lives of patients and the professionals who care for them.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Outset Medical, Inc.’s Item 2.02 8-K filed August 6, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Outset Medical, Inc. has no earnings call transcript available.